Serum Cystatin C Is an Early Predictive Biomarker of Acute Kidney Injury after Pediatric Cardiopulmonary Bypass | Zendy

Catherine D. Krawczeski | Zendy; René G. VanDeVoorde | Zendy; Thelma Kathman | Zendy; Michael Bennett | Zendy; Jessica G. Woo | Zendy; Yu Wang | Zendy; Rachel E. Griffiths | Zendy; Prasad Devarajan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Serum Cystatin C Is an Early Predictive Biomarker of Acute Kidney Injury after Pediatric Cardiopulmonary Bypass

Author(s) -

Catherine D. Krawczeski,

René G. VanDeVoorde,

Thelma Kathman,

Michael Bennett,

Jessica G. Woo,

Yu Wang,

Rachel E. Griffiths,

Prasad Devarajan

Publication year - 2010

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.02040310

Subject(s) - cystatin c , medicine , acute kidney injury , biomarker , creatinine , cardiopulmonary bypass , renal function , gastroenterology , urology , cardiology , biochemistry , chemistry

Acute kidney injury (AKI) is a frequent complication of cardiopulmonary bypass (CPB). Serum creatinine (SCr), the current standard, is an inadequate marker for AKI since a delay occurs before SCr rises. Biomarkers that are sensitive and rapidly measurable could allow early intervention and improve patient outcomes. We investigated the value of serum cystatin C as an early biomarker for AKI after pediatric CPB.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research